XENE Xenon Pharmaceuticals Inc. - Common Shares
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 6, 2026
$38,02
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$36,0752-Wochen-Tief
$72,6652-Wochen-Hoch
Marktkapitalisierung (MRQ)
$3.68B
P/E (TTM)
-8.0
EPS (TTM)
$-4.74
Umsatz (TTM)
$0
Ihre Abzeichen
52W-Spanne
$36–$73
Analystenbewertung
BUY
Kursziel
$74
P/E
-8.0
ROE
-43.6%
Nettogewinnmarge
-4612.1%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
XENE Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$38.02
Marktkapitalisierung (MRQ)
$3.68B
P/E (TTM)
-8.0
EPS (TTM)
$-4.74
Umsatz (TTM)
$0
ROE (TTM)
-43.6%
52W-Spanne
$36–$73
XENE Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Über Xenon Pharmaceuticals Inc. - Common Shares Unternehmensübersicht von Wikipedia
SektorHealthcare
BrancheBiotechnology
Mitarbeiter358
LandCA
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$8M2016-12-31 → 2025-12-31
EPS$-4.362016-12-31 → 2025-12-31
Freier Cashflow$-280M2016-12-31 → 2025-12-31
Nettogewinnmarge-4612.1%2016-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | XENE | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | -8.05-Jahres-Durchschnitt ≈-15.4 | ≈-15.4 | · | · | |
| P/S | 405.65-Jahres-Durchschnitt ≈275.7 | ≈275.7 | 10.3 | Überbewertet | |
| K/B (MRQ) | 3.05-Jahres-Durchschnitt ≈4.0 | ≈4.0 | 3.7 | Überbewertet | |
| Kurs / FCF (TTM) | -10.95-Jahres-Durchschnitt ≈-19.8 | ≈-19.8 | · | · | |
| Kurs / Cashflow (TTM) | -10.95-Jahres-Durchschnitt ≈-20.3 | ≈-20.3 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 5.25-Jahres-Durchschnitt ≈4.0 | ≈4.0 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | XENE | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Operating Margin (Betriebsgewinnmarge) | -4974.3%5-Jahres-Durchschnitt ≈-2257.2% | ≈-2257.2% | -588.2% | Schwach | |
| EBITDA Margin (EBITDA-Marge) | -4974.3%5-Jahres-Durchschnitt ≈-2257.2% | ≈-2257.2% | -588.2% | Schwach | |
| Pretax Margin (Vorgewinnmarge) | -4598.6%5-Jahres-Durchschnitt ≈-2118.1% | ≈-2118.1% | · | · | |
| Net Profit Margin (Nettogewinnmarge) | -4612.1%5-Jahres-Durchschnitt ≈-2123.0% | ≈-2123.0% | -507.2% | Schwach | |
| ROA (TTM) | -41.5%5-Jahres-Durchschnitt ≈-27.2% | ≈-27.2% | -29.6% | Schwach | |
| ROE (TTM) | -43.6%5-Jahres-Durchschnitt ≈-29.4% | ≈-29.4% | -42.0% | Schwach | |
| ROIC | -64.3%5-Jahres-Durchschnitt ≈-31.2% | ≈-31.2% | · | · |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | XENE | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 21.05-Jahres-Durchschnitt ≈24.1 | ≈24.1 | 9.6 | Starke Liquidität | |
| Quick Ratio | 13.15-Jahres-Durchschnitt ≈23.8 | ≈23.8 | 6.6 | Starke Liquidität |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | XENE | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue CAGR 3Y (Umsatz CAGR 3J) | -7.4% | · | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | -25.3% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | XENE | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.05-Jahres-Durchschnitt ≈0.0 | ≈0.0 | 0.2 | Schwach | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$20.9K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
1.1%
Nächster Bericht
Nov 02, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 12, 2026 | $-1.11 | $-1.16 | 4.4% |
| 31. März 2026 | Mai 12, 2026 | $-1.17 | $-1.21 | 3.1% |
| 31. Dezember 2025 | $-1.31 | $-1.22 | -7.8% | |
| 30. September 2025 | $-1.15 | $-1.18 | 2.1% | |
| 30. Juni 2025 | $-1.07 | $-1.01 | -5.8% | |
| 31. März 2025 | $-0.83 | $-0.93 | 10.8% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $0 | $0 | $9M | $18M | $32M | $7M | · | $311.0K | $2M | $16M | $28M | |
| R&D Expense | $301M | $210M | $168M | $106M | $75M | $51M | $39M | $24M | $26M | $20M | $15M | $12M | |
| SG&A Expense | $80M | $69M | $47M | $33M | $22M | $13M | $11M | $8M | $7M | $7M | $10M | $5M | |
| Operating Expenses | $381M | $279M | $214M | $139M | $97M | $63M | $50M | $38M | $33M | $27M | $25M | $17M | |
| Operating Income | $-373M | $-279M | $-214M | $-129M | $-79M | $-31M | $-43M | $-38M | $-33M | $-25M | $-9M | $11M | |
| Interest Expense | · | · | · | · | · | $484.0K | $1M | $1M | · | · | · | · | |
| Interest Income | $27M | $42M | $28M | $9M | $466.0K | $2M | $2M | $1M | $477.0K | $504.0K | $542.0K | $568.0K | |
| Other Non-op | $28M | $41M | $31M | $4M | $105.0K | $2M | · | · | · | · | · | · | |
| Pretax Income | $-345M | $-238M | $-183M | $-125M | $-79M | $-29M | $-42M | $-35M | · | · | · | · | |
| Income Tax | $1M | $-4M | $-292.0K | $118.0K | $-6.0K | $-257.0K | $-23.0K | $-24.0K | · | · | · | $0 | |
| Net Income | $-346M | $-234M | $-182M | $-125M | $-79M | $-29M | $-42M | $-34M | $-31M | $-23M | $-16M | $13M | |
| EPS (Basic) | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 | $-0.81 | · | $-1.63 | $-1.71 | $-1.48 | $-1.10 | $4.11 | |
| EPS (Diluted) | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 | $-0.81 | · | $-1.63 | $-1.72 | $-1.48 | $-1.10 | $3.28 | |
| Shares (Basic) | 79,253,751 | 77,894,643 | 66,889,005 | 60,542,142 | 43,627,452 | 34,542,213 | · | 19,425,711 | 17,985,061 | 15,493,474 | 14,281,837 | 3,165,572 | |
| Shares (Diluted) | 79,253,751 | 77,894,643 | 66,889,005 | 60,542,142 | 43,627,452 | 34,542,213 | · | 19,425,711 | 18,001,759 | 15,493,474 | 14,281,837 | 3,963,797 | |
| EBITDA | $-373M | $-279M | $-214M | $-129M | $-79M | $-31M | $-43M | $-38M | $-33M | $-25M | $-9M | $12M |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $199M | $143M | $149M | $57M | $176M | $45M | $25M | $68M | $20M | $17M | $59M | $72M | |
| Short-term Investments | $350M | $484M | $489M | $535M | $376M | $132M | $117M | $52M | $23M | $47M | · | $12M | |
| Receivables | · | $1M | $874.0K | $986.0K | $3M | $2M | $813.0K | $151.0K | $438.0K | $200.0K | $315.0K | $215.0K | |
| Prepaid Expense | $10M | $7M | $6M | $7M | $4M | $3M | $3M | $2M | $716.0K | $1M | $2M | $686.0K | |
| Current Assets | $561M | $635M | $645M | $600M | $559M | $182M | $145M | $121M | $45M | $66M | $61M | $85M | |
| PP&E (Net) | $9M | $10M | $10M | $6M | $4M | $4M | $2M | $991.0K | $1M | $1M | $2M | $2M | |
| Accum. Depreciation | $15M | $13M | $11M | $9M | $13M | $15M | $15M | $16M | $16M | $15M | $15M | $14M | |
| Total Assets | $633M | $798M | $965M | $754M | $572M | $189M | $148M | $122M | $46M | $67M | $64M | $87M | |
| Accounts Payable | $40M | $34M | $26M | $22M | $14M | $11M | $9M | $4M | $3M | $4M | $3M | $3M | |
| Accrued Liabilities | $36M | · | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $42M | $36M | $27M | $23M | $14M | $15M | $43M | $4M | $4M | $4M | $3M | $14M | |
| Capital Leases | $6M | $8M | $10M | $10M | $8M | $3M | $743.0K | · | · | · | · | · | |
| Other Non-current Liabilities | $3M | $0 | · | · | · | · | · | · | · | · | · | · | |
| Total Liabilities | $51M | $43M | $37M | $33M | $22M | $18M | $56M | $19M | $10M | $4M | $3M | $15M | |
| Long-term Debt | · | · | · | · | · | · | $16M | · | $7M | · | · | · | |
| Total Debt | · | · | · | · | · | · | $16M | $15M | $7M | · | · | · | |
| Common Stock | $1.60B | $1.46B | $1.44B | $1.07B | $783M | $398M | $294M | $266M | $174M | $173M | $149M | $147M | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | · | · | $30M | |
| Retained Earnings | $-1.25B | $-899M | $-665M | $-483M | $-357M | $-278M | $-250M | $-208M | $-173M | $-143M | $-120M | $-104M | |
| AOCI | $335.0K | $-2M | $-77.0K | $-3M | $-990.0K | $-990.0K | $-990.0K | $-990.0K | $-990.0K | $-990.0K | $-990.0K | $-990.0K | |
| Stockholders' Equity | $582M | $755M | $928M | $721M | $550M | $171M | $92M | $103M | $36M | $64M | $61M | $73M | |
| Liabilities + Equity | $633M | $798M | $965M | $754M | $572M | $189M | $148M | $122M | $46M | $67M | $64M | $87M | |
| Shares Outstanding | 80,010,790 | 76,416,086 | 75,370,977 | 62,587,701 | 51,634,752 | 35,012,125 | 28,139,228 | 25,750,721 | 17,998,420 | 17,930,590 | 14,385,336 | 14,181,333 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3M | $3M | $2M | $1M | $906.0K | $644.0K | $429.0K | $586.0K | $649.0K | $864.0K | $1M | $738.0K | |
| Stock-based Comp | $54M | $51M | $32M | $20M | $10M | $6M | $3M | $3M | $2M | $2M | $4M | $760.0K | |
| Deferred Tax | $-3M | $-9M | $-292.0K | $-44.0K | $58.0K | $-285.0K | $-133.0K | $-105.0K | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | · | · | $-14M | |
| Operating Cash Flow | $-279M | $-181M | $-151M | $-101M | $-70M | $-48M | $-5M | $-35M | $-29M | $-20M | $-18M | $266.0K | |
| CapEx | $799.0K | $3M | $6M | $3M | $2M | $3M | $1M | $507.0K | $315.0K | $279.0K | $551.0K | $2M | |
| Investing Cash Flow | $218M | $165M | $-111M | $-293M | $-247M | $-17M | $-66M | $-29M | $24M | · | · | · | |
| Stock Issued | · | · | · | · | · | $102M | $27M | $103M | · | $24M | $278.0K | $43M | |
| Net Stock Activity | · | · | · | · | · | $102M | $27M | $103M | · | $24M | $278.0K | $43M | |
| Financing Cash Flow | $117M | $12M | $354M | $278M | $448M | $86M | $28M | $112M | $7M | · | · | · | |
| Net Change in Cash | $56M | $-6M | $91M | $-118M | $131M | $20M | $-43M | $47M | $3M | $-42M | $-13M | $34M | |
| Taxes Paid | $8M | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-280M | $-184M | $-151M | $-101M | $-72M | $-51M | $-6M | $-35M | $-29M | $-20M | $-19M | $-1M | |
| Levered FCF | · | · | · | · | · | $-51M | $-7M | · | · | · | · | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -4974.3% | · | · | -1368.9% | -428.5% | -97.3% | -627.0% | · | -10474.3% | -1376.4% | -60.1% | 39.1% | |
| Net Margin | -4612.1% | · | · | -1329.0% | -427.9% | -89.6% | -609.1% | · | -9872.7% | -1275.5% | -101.1% | 45.9% | |
| Pretax Margin | -4598.6% | · | · | -1327.7% | -427.9% | -90.5% | -609.4% | · | · | · | · | · | |
| EBITDA Margin | -4974.3% | · | · | -1368.9% | -428.5% | -97.3% | -627.0% | · | -10474.3% | -1376.4% | -60.1% | 41.8% | |
| ROA | -48.3% | -26.6% | -21.2% | -18.9% | -20.7% | -17.1% | -30.8% | -40.9% | -54.0% | -35.0% | -20.8% | 18.4% | |
| ROE | -56.9% | -30.2% | -23.3% | -17.0% | -19.8% | -16.3% | -50.0% | -32.2% | -61.5% | -36.8% | -23.5% | -465.5% | |
| ROIC | -64.3% | -36.4% | -23.0% | -17.9% | -14.4% | -18.1% | -39.8% | · | · | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.4 | 17.8 | 23.6 | 26.4 | 39.0 | 12.3 | 3.3 | 29.5 | 11.0 | 18.7 | 21.9 | 5.9 | |
| Quick Ratio | 13.1 | 17.7 | 23.4 | 26.1 | 38.7 | 12.1 | 3.3 | 29.0 | 10.8 | 18.3 | 21.2 | 5.9 | |
| Debt / Equity | · | · | · | · | · | · | 0.2 | 0.1 | 0.2 | · | · | · | |
| LT Debt / Equity | · | · | · | · | · | · | 0.1 | 0.1 | 0.2 | · | · | · | |
| Interest Coverage | · | · | · | · | · | -64.7 | -29.9 | -27.3 | · | · | · | · |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | · | 0.0 | 0.0 | 0.2 | 0.1 | · | 0.0 | 0.0 | 0.2 | 0.4 | |
| Receivables Turnover | · | · | · | 5.0 | 8.0 | 24.4 | 14.2 | · | 1.0 | 7.0 | 58.8 | 86.6 |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.27 | $9.88 | $12.31 | $11.53 | $10.65 | $4.89 | $3.27 | $4.01 | $2.00 | $3.56 | $4.24 | $5.13 | |
| Revenue / Share | $0.09 | · | · | $0.16 | · | · | · | · | $0.02 | $0.12 | $1.09 | $7.16 | |
| Cash Flow / Share | $-3.52 | $-2.33 | $-2.17 | $-1.63 | · | · | · | $-1.79 | $-1.60 | $-1.26 | $-1.27 | $0.07 | |
| Cash / Share | $2.49 | $1.87 | $1.97 | $0.91 | $3.40 | $1.29 | $0.88 | $2.63 | $1.14 | $0.95 | $4.08 | $5.08 | |
| EPS (TTM) | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 | $-0.81 | $-1.87 | $-1.63 | $-1.72 | $-1.48 | $-1.10 | $3.28 |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | · | -48.8% | -42.7% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -7.4% | · | · | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -25.3% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $8M | $0 | $0 | $9M | $18M | $32M | $7M | $311.0K | $311.0K | $2M | $16M | $28M | |
| Net Income TTM | $-346M | $-234M | $-182M | $-125M | $-79M | $-29M | $-42M | $-34M | $-31M | $-23M | $-16M | $13M | |
| Market Cap | $3.59B | $3.00B | $3.47B | $2.47B | $1.61B | $538M | $369M | $162M | $51M | $138M | $116M | $280M | |
| Enterprise Value | · | · | · | · | · | · | $243M | $58M | $14M | · | · | · | |
| P/E | -10.3 | -13.0 | -16.9 | -19.1 | -17.6 | -19.0 | -7.0 | -3.9 | -1.6 | -5.2 | -7.3 | 6.0 | |
| P/S | 478.1 | · | · | 261.6 | 87.5 | 16.7 | 54.0 | 522.5 | 163.5 | 76.6 | 7.4 | 9.9 | |
| P/B | 6.2 | 4.0 | 3.7 | 3.4 | 2.9 | 3.1 | 4.0 | 1.6 | 1.4 | 2.2 | 1.9 | 3.8 | |
| P / Tangible Book | 6.2 | 4.0 | 3.7 | 3.4 | 2.9 | 3.1 | · | · | · | · | · | · | |
| P / Cash Flow | -12.8 | -16.5 | -23.9 | -25.1 | -23.2 | -11.2 | -79.6 | -4.7 | -1.8 | -7.1 | -6.4 | 1052.9 | |
| P / FCF | -12.8 | -16.2 | -23.0 | -24.4 | -22.5 | -10.6 | -62.8 | -4.6 | -1.8 | -7.0 | -6.2 | -221.8 | |
| EV / EBITDA | · | · | · | · | · | · | -5.7 | -1.5 | -0.4 | · | · | · | |
| EV / FCF | · | · | · | · | · | · | -41.4 | -1.7 | -0.5 | · | · | · | |
| EV / Revenue | · | · | · | · | · | · | 35.6 | 187.1 | 45.0 | · | · | · | |
| Earnings Yield | -9.7% | -7.7% | -5.9% | -5.2% | -5.7% | -5.3% | -14.3% | -25.8% | -60.9% | -19.2% | -13.7% | 16.6% |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $8M | $0 | $0 | $0 | $0 | · | · | · | · | $0 | $132.0K | |
| R&D Expense | $99M | $89M | $88M | $77M | $75M | $61M | $59M | $57M | $50M | $44M | $41M | $43M | $44M | $40M | $35M | $29M | |
| SG&A Expense | $24M | $24M | $22M | $19M | $19M | $19M | $18M | $17M | $19M | $15M | $13M | $13M | $12M | $10M | $9M | $9M | |
| Operating Expenses | $123M | $112M | $110M | $96M | $94M | $80M | $77M | $74M | $69M | $59M | $54M | $56M | $56M | $49M | $43M | $38M | |
| Operating Income | $-123M | $-112M | $-110M | $-96M | $-94M | $-73M | $-77M | $-74M | $-69M | $-59M | $-54M | $-56M | $-56M | $-49M | $-43M | $-38M | |
| Interest Income | $12M | $7M | $5M | $6M | $7M | $8M | $9M | $10M | $11M | $11M | $9M | $7M | $7M | $5M | $4M | $3M | |
| Other Non-op | $12M | $7M | $5M | $6M | $9M | $8M | $8M | $11M | $11M | $12M | $9M | $7M | $8M | $8M | $7M | $391.0K | |
| Pretax Income | $-111M | $-105M | $-105M | $-90M | $-85M | $-65M | $-70M | $-63M | $-58M | $-48M | $-45M | $-49M | $-48M | $-41M | $-36M | $-38M | |
| Income Tax | $-585.0K | $-3M | $538.0K | $677.0K | $-626.0K | $427.0K | $-4M | $-320.0K | $-333.0K | $412.0K | $-205.0K | $-157.0K | $-220.0K | $290.0K | $1M | $-587.0K | |
| Net Income | $-111M | $-102M | $-105M | $-91M | $-85M | $-65M | $-66M | $-63M | $-58M | $-48M | $-45M | $-48M | $-47M | $-42M | $-37M | $-37M | |
| EPS (Basic) | $-1.11 | $-1.17 | $-1.31 | $-1.15 | $-1.07 | $-0.83 | $-0.83 | $-0.81 | $-0.75 | $-0.62 | $-0.65 | $-0.73 | $-0.72 | $-0.63 | $-0.59 | $-0.57 | |
| EPS (Diluted) | $-1.11 | $-1.17 | $-1.31 | $-1.15 | $-1.07 | $-0.83 | $-0.83 | $-0.81 | $-0.75 | $-0.62 | $-0.65 | $-0.73 | $-0.72 | $-0.63 | $-0.59 | $-0.57 | |
| Shares (Basic) | 99,609,804 | 87,345,717 | · | 79,247,976 | 78,953,445 | 78,687,503 | · | 77,926,205 | 77,671,128 | 77,594,599 | · | 66,002,163 | 65,861,138 | 65,724,681 | · | 65,465,069 | |
| Shares (Diluted) | 99,609,804 | 87,345,717 | · | 79,247,976 | 78,953,445 | 78,687,503 | · | 77,926,205 | 77,671,128 | 77,594,599 | · | 66,002,163 | 65,861,138 | 65,724,681 | · | 65,465,069 | |
| EBITDA | $-123M | $-112M | · | $-96M | $-94M | $-73M | · | $-74M | $-69M | $-59M | · | $-56M | $-56M | $-49M | · | $-38M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $120M | $546M | $199M | $105M | $135M | $117M | $143M | $88M | $137M | $59M | · | $100M | $65M | $70M | · | $103M | |
| Short-term Investments | $811M | $549M | $350M | $358M | $352M | $433M | $484M | $566M | $585M | $641M | · | $427M | $475M | $458M | · | $535M | |
| Receivables | · | · | · | · | · | · | · | $938.0K | $853.0K | $833.0K | · | $805.0K | $2M | $2M | · | $2M | |
| Prepaid Expense | $14M | $11M | $10M | $17M | $12M | $7M | $7M | $5M | $6M | $7M | · | $4M | $3M | $4M | · | $9M | |
| Current Assets | $946M | $1.11B | $561M | $480M | $500M | $566M | $635M | $660M | $728M | $707M | · | $531M | $545M | $533M | · | $649M | |
| PP&E (Net) | $8M | $8M | $9M | $9M | $9M | $10M | $10M | $10M | $10M | $9M | · | $10M | $10M | $8M | · | $5M | |
| Accum. Depreciation | · | · | $15M | · | · | · | $13M | · | · | · | · | · | · | · | · | · | |
| Total Assets | $1.30B | $1.39B | $633M | $608M | $674M | $743M | $798M | $836M | $884M | $919M | · | $671M | $685M | $720M | · | $776M | |
| Accounts Payable | $44M | $38M | $40M | $37M | $32M | $31M | $34M | $28M | $30M | $21M | · | $23M | $27M | $21M | · | $16M | |
| Accrued Liabilities | $41M | $33M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $45M | $40M | $42M | $38M | $33M | $32M | $36M | $30M | $31M | $22M | · | $25M | $28M | $22M | · | $16M | |
| Capital Leases | $5M | $6M | $6M | $7M | $7M | $7M | $8M | $8M | $9M | $9M | · | $10M | $10M | $10M | · | $7M | |
| Other Non-current Liabilities | $3M | $3M | $3M | $3M | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Total Liabilities | $53M | $49M | $51M | $48M | $40M | $39M | $43M | $38M | $40M | $31M | · | $35M | $38M | $33M | · | $23M | |
| Common Stock | $2.43B | $2.42B | $1.60B | $1.48B | $1.47B | $1.46B | $1.46B | $1.44B | $1.44B | $1.44B | · | $1.12B | $1.08B | $1.07B | · | $1.06B | |
| Retained Earnings | $-1.46B | $-1.35B | $-1.25B | $-1.14B | $-1.05B | $-965M | $-899M | $-834M | $-771M | $-713M | · | $-620M | $-572M | $-524M | · | $-445M | |
| AOCI | $-3M | $-1M | $335.0K | $477.0K | $113.0K | $-836.0K | $-2M | $1M | $-2M | $-2M | · | $-3M | $-3M | $-2M | · | $-3M | |
| Stockholders' Equity | $1.24B | $1.34B | $582M | $560M | $634M | $704M | $755M | $798M | $844M | $888M | $928M | $637M | $646M | $687M | $721M | $753M | |
| Liabilities + Equity | $1.30B | $1.39B | $633M | $608M | $674M | $743M | $798M | $836M | $884M | $919M | · | $671M | $685M | $720M | · | $776M | |
| Shares Outstanding | 96,752,884 | 96,624,123 | 80,010,790 | 77,120,168 | 76,939,811 | 76,586,359 | 76,416,086 | 75,794,409 | 75,667,550 | 75,459,681 | · | 65,002,249 | 63,718,350 | 63,107,020 | · | 62,542,542 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $558.0K | $587.0K | $611.0K | $641.0K | $632.0K | $659.0K | $666.0K | $636.0K | $628.0K | $586.0K | $-629.0K | $2M | $602.0K | $354.0K | $296.0K | $358.0K | |
| Stock-based Comp | $17M | $17M | $14M | $14M | $14M | $12M | $14M | $13M | $15M | $9M | $9M | $9M | $8M | $6M | $6M | $6M | |
| Deferred Tax | $-2M | $447.0K | $-1M | $-701.0K | $-170.0K | $-1M | $-9M | $-322.0K | $-333.0K | $403.0K | $-200.0K | $-156.0K | $-224.0K | $288.0K | $5.0K | $-203.0K | |
| Operating Cash Flow | $-95M | $-89M | $-81M | $-72M | $-64M | $-62M | $-54M | $-51M | $-34M | $-46M | $-35M | $-48M | $-33M | $-34M | $-35M | $-30M | |
| CapEx | $275.0K | $133.0K | $318.0K | $281.0K | $157.0K | $43.0K | $783.0K | $590.0K | $2M | $188.0K | $78.0K | $1M | $2M | $2M | $2M | $386.0K | |
| Investing Cash Flow | $-331M | $-407M | $63M | $39M | $82M | $35M | $99M | $2M | $112M | $-43M | $-240M | $54M | $28M | $47M | $-12M | $-234M | |
| Financing Cash Flow | $26.0K | $843M | $114M | $2M | $65.0K | $1M | $12M | $0 | $0 | $0 | $324M | · | · | · | $6.0K | $699.0K | |
| Net Change in Cash | $-426M | $347M | $95M | $-31M | $19M | $-26M | $55M | $-49M | $78M | $-90M | $49M | $35M | $-5M | $12M | $-46M | $-266M | |
| Free Cash Flow | · | $-89M | · | · | · | $-62M | · | · | · | $-43M | · | · | · | $-37M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | -969.8% | · | · | · | · | · | · | · | · | · | -28884.8% | |
| Net Margin | · | · | · | · | · | -867.3% | · | · | · | · | · | · | · | · | · | -28143.9% | |
| Pretax Margin | · | · | · | · | · | -861.6% | · | · | · | · | · | · | · | · | · | -28588.6% | |
| EBITDA Margin | · | · | · | · | · | -969.8% | · | · | · | · | · | · | · | · | · | -28884.8% | |
| ROA | -11.2% | -9.6% | · | -12.6% | -10.9% | -7.8% | · | -8.3% | -7.4% | -5.9% | · | -6.7% | -6.4% | -6.5% | · | -7.1% | |
| ROE | -11.8% | -10.0% | · | -13.4% | -11.5% | -8.2% | · | -8.8% | -7.8% | -6.1% | · | -7.0% | -6.6% | -6.8% | · | -7.4% | |
| ROIC | -9.9% | -8.2% | · | -17.3% | -14.8% | -10.4% | · | -9.2% | -8.1% | -6.7% | · | -8.7% | -8.6% | -7.2% | · | -5.0% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 21.0 | 27.8 | · | 12.5 | 15.1 | 17.7 | · | 22.2 | 23.3 | 31.8 | · | 21.5 | 19.3 | 23.7 | · | 41.8 | |
| Quick Ratio | 20.7 | 27.5 | · | 12.1 | 14.8 | 17.2 | · | 22.1 | 23.1 | 31.5 | · | 21.3 | 19.2 | 23.5 | · | 41.2 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · | 0.0 | |
| Receivables Turnover | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $12.84 | $13.85 | · | $7.26 | $8.24 | $9.19 | · | $10.53 | $11.15 | $11.76 | · | $9.79 | $10.15 | $10.89 | · | $12.04 | |
| Revenue / Share | $0.00 | $0.00 | · | $0.00 | $0.00 | $0.10 | · | · | · | · | · | · | · | · | · | $0.00 | |
| Cash Flow / Share | · | $-1.02 | · | · | · | $-0.78 | · | · | · | $-0.56 | · | · | · | $-0.52 | · | · | |
| Cash / Share | $1.24 | $5.65 | · | $1.36 | $1.76 | $1.52 | · | $1.16 | $1.81 | $0.78 | · | $1.53 | $1.01 | $1.10 | · | $1.65 | |
| EPS (TTM) | $-4.74 | $-4.70 | · | $-3.88 | $-3.54 | $-3.22 | · | $-2.83 | $-2.75 | $-2.72 | · | $-2.67 | $-2.51 | $-2.34 | · | $-1.95 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | · | $8M | $8M | $8M | · | · | · | · | · | $9M | $9M | $9M | · | $13M | |
| Net Income TTM | $-409M | $-383M | · | $-306M | $-278M | $-251M | · | $-213M | $-199M | $-189M | · | $-175M | $-164M | $-147M | · | $-114M | |
| Market Cap | $5.84B | $5.62B | · | $3.10B | $2.41B | $2.57B | · | $2.98B | $2.95B | $3.25B | · | $2.22B | $2.45B | $2.26B | · | $2.26B | |
| P/E | -12.7 | -12.4 | · | -10.3 | -8.8 | -10.4 | · | -13.9 | -14.2 | -15.8 | · | -12.8 | -15.3 | -15.3 | · | -18.5 | |
| P/S | · | · | · | 412.9 | 321.1 | 342.6 | · | · | · | · | · | 235.4 | 260.0 | 239.4 | · | 171.4 | |
| P/B | 4.7 | 4.2 | · | 5.5 | 3.8 | 3.6 | · | 3.7 | 3.5 | 3.7 | · | 3.5 | 3.8 | 3.3 | · | 3.0 | |
| P / Tangible Book | 4.7 | 4.2 | · | 5.5 | 3.8 | 3.6 | · | 3.7 | 3.5 | 3.7 | · | 3.5 | 3.8 | 3.3 | · | 3.0 | |
| P / Cash Flow | · | -63.2 | · | · | · | -41.7 | · | · | · | -75.2 | · | · | · | -65.6 | · | · | |
| Earnings Yield | -7.8% | -8.1% | · | -9.7% | -11.3% | -9.6% | · | -7.2% | -7.0% | -6.3% | · | -7.8% | -6.5% | -6.5% | · | -5.4% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $8M | $0 | $0 | $9M | $18M |
| Betriebsgewinnmarge % | -4974.3% | · | · | -1368.9% | -428.5% |
| Nettoergebnis | $-346M | $-234M | $-182M | $-125M | $-79M |
| Verwässerte EPS | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 13.4 | 17.8 | 23.6 | 26.4 | 39.0 |
| Quick Ratio | 13.1 | 17.7 | 23.4 | 26.1 | 38.7 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-280M | $-184M | $-151M | $-101M | $-72M |
Institutionelle Eigentümer (13F) 331 Einreicher · $5.9B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
331
Gehaltener Wert
$5.9B
Neue Positionen
50
Geschlossene Positionen
22
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 50 (-32 vs. Vorquartal) | 22 (-10 vs. Vorquartal) | 121 (-10 vs. Vorquartal) | 91 (+33 vs. Vorquartal) | -6.9M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| FMR LLC | $582.353.159 | 9.647.998 | 9,95% | Aktien |
| BlackRock, Inc. | $454.057.014 | 7.522.482 | 7,76% | Aktien |
| Avoro Capital Advisors LLC | $348.746.620 | 5.777.777 | 5,96% | Aktien |
| Polar Capital Holdings Plc | $275.878.760 | 4.570.556 | 4,72% | Aktien |
| Driehaus Capital Management LLC | $266.704.101 | 4.418.557 | 4,56% | Aktien |
| JANUS HENDERSON GROUP PLC | $242.858.453 | 4.175.982 | 4,15% | Aktien |
| JPMORGAN CHASE & CO | $157.381.859 | 2.617.360 | 2,69% | Aktien |
| Capital International Investors | $142.548.530 | 2.361.639 | 2,44% | Aktien |
| STATE STREET CORP | $118.885.244 | 1.969.629 | 2,03% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $99.162.305 | 1.642.848 | 1,69% | Aktien |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $97.523.411 | 1.615.696 | 1,67% | Aktien |
| Affinity Asset Advisors, LLC | $96.274.200 | 1.595.000 | 1,65% | Aktien |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $90.980.266 | 1.507.294 | 1,56% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $90.846.349 | 1.562.276 | 1,55% | Aktien |
| FRANKLIN RESOURCES INC | $86.780.296 | 1.437.712 | 1,48% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $86.042.698 | 1.425.492 | 1,47% | Aktien |
| CITADEL ADVISORS LLC | $84.578.967 | 1.401.242 | 1,45% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $82.692.689 | 1.370.114 | 1,41% | Aktien |
| Siren, L.L.C. | $79.588.523 | 1.318.564 | 1,36% | Aktien |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $77.908.522 | 1.290.731 | 1,33% | Aktien |
| Pictet Asset Management Holding SA | $71.645.411 | 1.187.723 | 1,22% | Aktien |
| BRAIDWELL LP | $68.294.443 | 1.131.452 | 1,17% | Aktien |
| Nuveen, LLC | $59.945.086 | 993.126 | 1,02% | Aktien |
| Invesco Ltd. | $54.532.726 | 903.458 | 0,93% | Aktien |
| ORBIMED ADVISORS LLC | $53.869.550 | 892.471 | 0,92% | Aktien |
| Caligan Partners LP | $53.717.020 | 889.944 | 0,92% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $53.377.571 | 884.319 | 0,91% | Aktien |
| FEDERATED HERMES, INC. | $53.342.365 | 883.737 | 0,91% | Aktien |
| Capital World Investors | $52.077.099 | 862.775 | 0,89% | Aktien |
| GOLDMAN SACHS GROUP INC | $46.696.005 | 773.625 | 0,80% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $45.248.934 | 749.651 | 0,77% | Aktien |
| Caption Management, LLC | $43.942.080 | 728.000 | 0,75% | Kaufoption |
| Vestal Point Capital, LP | $42.252.000 | 700.000 | 0,72% | Aktien |
| Alyeska Investment Group, L.P. | $42.112.689 | 697.692 | 0,72% | Aktien |
| MARSHALL WACE, LLP | $41.608.683 | 689.342 | 0,71% | Aktien |
| Rock Springs Capital Management LP | $41.280.627 | 683.907 | 0,71% | Aktien |
| NORTHERN TRUST CORP | $40.535.724 | 671.566 | 0,69% | Aktien |
| PANAGORA ASSET MANAGEMENT INC | $40.080.911 | 664.031 | 0,69% | Aktien |
| First Turn Management, LLC | $36.228.072 | 600.200 | 0,62% | Aktien |
| TUDOR INVESTMENT CORP ET AL | $32.919.559 | 545.387 | 0,56% | Aktien |
| LOOMIS SAYLES & CO L P | $31.826.198 | 527.273 | 0,54% | Aktien |
| VANGUARD GROUP INC | $29.789.210 | 664.641 | 0,51% | Aktien |
| Octagon Capital Advisors LP | $29.576.400 | 490.000 | 0,51% | Aktien |
| NOVO HOLDINGS A/S | $29.301.038 | 485.438 | 0,50% | Aktien |
| Candriam S.C.A. | $27.905.802 | 462.768 | 0,48% | Aktien |
| Logos Global Management LP | $27.162.000 | 450.000 | 0,46% | Aktien |
| Trails Edge Capital Partners, LP | $26.558.400 | 440.000 | 0,45% | Aktien |
| Bank of New York Mellon Corp | $25.442.801 | 421.518 | 0,43% | Aktien |
| ALGERT GLOBAL LLC | $25.337.498 | 419.773 | 0,43% | Aktien |
| Aberdeen Group plc | $24.671.305 | 408.736 | 0,42% | Aktien |
Unternehmensinsider 32 Insider · 15 Führungskräfte · 16 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Ian Mortimer | PRESIDENT & CEO | 30. September 2026 P | 49.923 | 1 | 17 | $-19.172.642 |
| Thomas Patrick Kelly | Chief Financial Officer | 30. September 2026 P | 15.000 | 1 | 0 | $559.800 |
| Sherry Aulin | Chief Financial Officer | 18. Dezember 2024 M | 0 | 0 | 0 | $0 |
| Christopher John Kenney | Chief Medical Officer | 28. August 2026 S | 2 | 0 | 4 | $-670.274 |
| Andrea Difabio | Chief Legal Officer | 12. März 2026 M | 7.301 | 0 | 2 | $-230.812 |
| Darren S Cline | Chief Commercial Officer | 9. Januar 2026 A | · | 0 | 0 | $0 |
| Christopher Von Seggern | Chief Commercial Officer | 11. März 2024 A | 4.000 | 0 | 0 | $0 |
| James R. Empfield | EVP, Drug Discovery | 11. März 2024 A | 10.000 | 0 | 0 | $0 |
| Sherrington Robin | EVP, Strategy & Innovation | 11. März 2024 A | 8.398 | 0 | 0 | $0 |
| Ernesto Aycardi-Fonseca | CMO | 12. März 2020 A | · | 0 | 0 | $0 |
| Charles J. Cohen | VP, Biology | 11. Dezember 2018 M | 6.550 | 0 | 0 | $0 |
| Paul Y. Goldberg | SVP, Clinical Development | 23. Oktober 2017 A | 6.000 | 0 | 0 | $0 |
| Raymond Winquist | Head, Translational Research | 18. August 2017 P | 1.000 | 0 | 0 | $0 |
| Karen G. Corraini | Gen. Counsel & Corp. Secretary | 17. März 2015 A | · | 0 | 0 | $0 |
| Gary Bridger | EVP, Research & Development | 21. November 2014 A | · | 0 | 0 | $0 |
| Dawn Svoronos | Direktor | 1. September 2026 M | 31.373 | 0 | 0 | $0 |
| Gillian Cannon | Direktor | 5. Juni 2026 S | 1.455 | 0 | 1 | $-63.237 |
| Gary Patou | Direktor | 5. Juni 2026 S | 24.896 | 0 | 1 | $-70.251 |
| Elizabeth A. Garofalo | Direktor | 3. Juni 2026 A | 2.645 | 0 | 0 | $0 |
| Justin D. Gover | Direktor | 3. Juni 2026 A | 2.645 | 0 | 0 | $0 |
| Patrick Machado | Direktor | 3. Juni 2026 A | 2.645 | 0 | 0 | $0 |
| Mohammad Azab | Direktor | 19. Dezember 2023 M | 74.225 | 0 | 0 | $0 |
| Simon N. Pimstone | Direktor | 2. Juni 2023 A | 6.000 | 0 | 0 | $0 |
| Michael R Hayden | Direktor | 3. Juni 2021 A | 116.206 | 0 | 0 | $0 |
| Frank A Holler | Direktor | 27. Mai 2021 M | 143.653 | 0 | 0 | $0 |
| Michael M Tarnow | Direktor | 18. Mai 2021 M | 77.942 | 0 | 0 | $0 |
| Clarissa Desjardins | Direktor | 1. Juni 2020 A | · | 0 | 0 | $0 |
| Richard H Scheller | Direktor | 16. September 2019 A | 7.000 | 0 | 0 | $0 |
| Johnston L Evans | Direktor | 4. Mai 2015 A | 444.655 | 0 | 0 | $0 |
| Evan A. Stein | Direktor | 30. April 2015 J | 4.172 | 0 | 0 | $0 |
| Associates, Llp Mx | 10%-Eigentümer | 31. Dezember 2014 J | 0 | 0 | 0 | $0 |
| Steven Gannon | · | 11. August 2026 S | 1.870 | 0 | 1 | $-640.600 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 24 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IBRN · iShares Trust | 4,47% | 5.685 SH | 11. September 2026 | Täglich |
| BBC · ETFis Series Trust I | 0,81% | 5.966 NS | 31. Juli 2026 | N-PORT |
| MEDI · Harbor ETF Trust | 0,51% | 3.362 NS | 31. Juli 2026 | N-PORT |
| IBB · iShares Trust | 0,40% | 694.342 SH | 11. September 2026 | Täglich |
| NUSC · Nushares ETF Trust | 0,38% | 78.317 NS | 31. Juli 2026 | N-PORT |
| IWO · iShares Trust | 0,38% | 923.340 SH | 11. September 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,35% | 104.976 SH | 19. August 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,25% | 6.839 SH | 2. Oktober 2026 | Täglich |
| RSSL · Global X Funds | 0,20% | 46.997 NS | 31. Juli 2026 | N-PORT |
| IWM · iShares Trust | 0,19% | 2.506.283 SH | 11. September 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,18% | 564.724 SH | 19. August 2026 | Täglich |
| ESML · iShares Trust | 0,17% | 82.755 SH | 11. September 2026 | Täglich |
| ESLG · Strategy Shares | 0,17% | 635 NS | 31. Juli 2026 | N-PORT |
| FFSM · FIDELITY COVINGTON TRUST | 0,12% | 28.362 NS | 31. Juli 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,07% | 38.542 NS | 31. Juli 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,06% | 3.866 SH | 2. Oktober 2026 | Täglich |
| WSML · iShares Trust | 0,04% | 4.898 SH | 11. September 2026 | Täglich |
| VFMO · VANGUARD WELLINGTON FUND | 0,04% | 14.319 SH | 19. August 2026 | Täglich |
| PDN · Invesco Exchange-Traded Fund Trust … | 0,03% | 2.490 SH | 2. Oktober 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 8.110 SH | 19. August 2026 | Täglich |
| ESGV · VANGUARD WORLD FUND | 0,01% | 21.635 SH | 19. August 2026 | Täglich |
| IWV · iShares Trust | 0,01% | 27.091 SH | 8. September 2026 | Täglich |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 77.770 SH | 19. August 2026 | Täglich |
| SMMV · iShares Trust | · | 26.325 SH | 1. September 2026 | Täglich |
XENE Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 26 Analysten
KAUF
Median-Ziel
$74.50
+95,9%
11 42,3%
Starker Kauf
14 53,8%
Kauf
1 3,8%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
18 Analysten · 2026-10-04Mittelwert-Ziel $74.31 +95,5%
← Unter allen Zielen
Aktueller Preis $38.02
Tief$46.00
Mittelwert$74.31
Hoch$97.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 6, 2026